Using AI, we identified publications that likely reported a testing or mutation rate, filtered publications for cancer type, and identified sentences that likely reported rates. Rates and covariates ...
SurvivorNet on MSN
Colon cancer is not one disease: Why BRAF & KRAS mutations matter
Today, doctors are increasingly looking at the genetic makeup of each patient’s tumor to guide treatment decisions.
A Marathon Not a Sprint: Improving Outcomes for Patients With Metastatic Melanoma in 2022 and Beyond This study showed variations in BRAF test results in TAT. One factor affecting this timeline is the ...
SurvivorNet on MSN
'Very promising': New cancer drug, Plixorafenib, shows promise for hard‑to‑treat brain tumors as FDA speeds its development
The U.S. Food and Drug Administration (FDA) has granted plixorafenib a Breakthrough Therapy Designation, signaling ...
A new report shows better than 80% concordance between liquid biopsy and tissue biopsy. Liquid biopsy and analysis of circulating tumor DNA (ctDNA) is a viable option for determining the presence of ...
NEW YORK, Sept 14 (Reuters) - Pfizer (PFE.N), opens new tab is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug Braftovi, which the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results